A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L)
A Randomized, Controlled, Open-Label, Multicenter, Phase II Study of the Safety and Efficacy of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer
Sponsor: Genentech, Inc.
Terminated
Based on data collected, the combination appeared to be poorly tolearated.
Other terminated trials from Genentech, Inc.
- Idiopathic Pulmonary Fibrosis · Phase PHASE2 · Jan 2026
- Non-small Cell Lung Cancer · Phase PHASE2 · Nov 2025
- Solid Tumour · Phase PHASE1 · Nov 2025
- Diffuse Large B-cell Lymphoma · Oct 2025
- Ulcerative Colitis · Phase PHASE2 · Jun 2025
More terminations from Genentech, Inc.
Other Non-Small Cell Lung Cancer trials with similar outcome
This PHASE2 trial investigates Non-Small Cell Lung Cancer and is currently terminated or withdrawn. Genentech, Inc. leads this study, which shows 8 recorded versions since 2007 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Apr 2022 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Mar 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Genentech, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.